Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Research and Innovation Action · Running

Fragment-Screen From fragments to high affinity binders interfacing integrated structural biology, medicinal chemistry and artificial intelligence

Coordinator
Instruct-Eric, United Kingdom
Runs
1 February 2023 to 31 January 2027
Status
Running
EU funding
€8.3m
Total cost
€8.3m
Partners
26 organisations in 11 countries
Type
Research and Innovation Action
Grant agreement
101094131

What the project is doing

In the project's own words, from its summary on CORDIS.

Fragment-Screen will develop innovative instrumentation, workflows and experimental and computational methodologies for fragment-based drug discovery (FBDD) enabling access to early phase structure-based drug discovery for all biological targets and for scientists both in industry and academia. The established workflows will use structural biology insights and associated data to feed artificial intelligence (AI) methodology to guide medicinal chemistry in drug development.

Fragment-Screen brings together scientists from four ESFRI Landmark research infrastructures (RIs): ESRF (the European synchrotron) and the distributed RIs EU-OPENSCREEN ERIC (medicinal chemistry), ELIXIR (data resources for life science) under the coordination of Instruct-ERIC (integrated structural biology) and seven industry partners in scientific instrumentation and computational and AI sectors including SMEs to remove crucial bottlenecks in early phase drug discovery.

The new instrumentation and workflows will be available at European RIs, while the new instruments will be commercialised to increase the technological competitiveness of European industry in drug design and the attractiveness of structural biology RIs for the pharmaceutical and biotech sectors. Fragment-Screen will implement open science approaches in early drug discovery to maximise the impact of screening campaigns.

Generated data will be made accessible so that iterative cycles applying AI will improve response times for drug discovery. We will create a framework for the objective and independent evaluation of AI in drug design to identify critical developments in this thriving research field. Methodologies for rigorous cross-validation will be established through demonstrator and pilot studies and results will be disseminated to the large scientific communities affiliated to the European RIs and beyond.

Topics

Who is involved

OrganisationCityCountryRole
Instruct-EricOxfordUnited KingdomCoordinator
Ibm Research GmbHRueschlikonSwitzerlandAssociatedpartner
Masarykova univerzitaBrnoCzechiaParticipant
Bruker Biospin GmbH & Co KgEttlingenGermanyParticipant
Bruker Biospin Holding SeEttlingenGermanyParticipant
European Infrastructure of Open Screening Platforms for Chemical Biology European Research Infrastucture Consortium (eu-Openscreen Eric)BerlinGermanyParticipant
European Molecular Biology LaboratoryHeidelbergGermanyParticipant
Johann Wolfgang Goethe-Universitaet Frankfurt Am MainFrankfurt Am MainGermanyParticipant
Signals GmbH & Co. KgFrankfurt Am MainGermanyParticipant
Danmarks Tekniske UniversitetKongens LyngbyDenmarkParticipant
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
AlpxGrenobleFranceParticipant
ArinaxMoiransFranceParticipant
European Synchrotron Radiation FacilityGrenobleFranceParticipant
Consorzio Interuniversitario Risonanze Magnetiche Di Metallo ProteineFirenzeItalyParticipant
Valsts zinatniskais instituts ""Nacionalais petniecibas un inovaciju instituts""""RigaLatviaParticipant
Fei Electron Optics BVEindhovenNetherlandsParticipant
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek ZiekenhuisAmsterdamNetherlandsParticipant
Universiteit UtrechtUtrechtNetherlandsParticipant
Faculdade De Ciencias Da Universidade De LisboaLisboaPortugalThird party
Fciencias.id - Associacao Para a Investigacao E Desenvolvimento De CienciasLisbonPortugalParticipant
Faculdade de Farmácia da Universidade de LisboaLisboaPortugalParticipant
Astex Therapeutics LimitedCambridgeUnited KingdomAssociatedpartner
Diamond Light Source LimitedDidcotUnited KingdomAssociatedpartner
United Kingdom Research and InnovationSwindonUnited KingdomAssociatedpartner
University of LeedsLeedsUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI